1. Home
  2. Directory
  3. California
  4. Palmdale
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1982947628

MAGDY AZIZ KEROLLOS BEBAWY O.D
Prescription History 1982947628
Optometrist in Palmdale, CA

NPI Status: Active since April 01, 2013

Contact Information

2720 E PALMDALE BLVD
PALMDALE, CA
ZIP 93550
Phone: (661) 267-0026

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MAGDY AZIZ KEROLLOS BEBAWY O.D, an active Optometrist specialist practicing in Palmdale, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 145 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 47 claims alone.

Medication Index

B
C
L
R
No matching medications currently found on file.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 42
30-Day Fills 54.3
Days Supply 1,523
CA State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills160.1
Peer Average Days Supply4,677
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,043.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.84

State Avg Cost Per Claim

$43.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Cyclosporine

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 29
30-Day Fills 38.0
Days Supply 1,140
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills48.0
Peer Average Days Supply1,425
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,606.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$503.68

State Avg Cost Per Claim

$516.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 47
30-Day Fills 68.0
Days Supply 1,852
CA State Average Benchmarks
Peer Average Claims159.0
Peer Average 30-Day Fills301.1
Peer Average Days Supply8,658
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,067.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.72

State Avg Cost Per Claim

$21.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 810
CA State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills122.0
Peer Average Days Supply3,636
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.2% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,887.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$699.55

State Avg Cost Per Claim

$947.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MAGDY AZIZ KEROLLOS BEBAWY O.D provides transparency into local medical care patterns within Palmdale, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.